Welcome to our dedicated page for Nexgel news (Ticker: NXGL), a resource for investors and traders seeking the latest updates and insights on Nexgel stock.
NEXGEL, Inc. (NASDAQ: NXGL) generates news across healthcare, consumer products, and capital markets through developments tied to its ultra-gentle, high-water-content hydrogel technology. The company regularly issues press releases on quarterly financial results, highlighting performance in its contract manufacturing segment and its portfolio of consumer-branded products in health, beauty, and OTC categories.
Investors following NXGL news will see updates on earnings announcements, including revenue trends, gross margin, operating expenses, and non-GAAP metrics such as EBITDA and Adjusted EBITDA. Management commentary often discusses demand for branded products, new contract manufacturing agreements, and the impact of partnerships with consumer healthcare companies.
NEXGEL’s news flow also covers strategic and corporate actions. Recent items include the spin-off of select drug delivery application assets into NexGelRx, with NEXGEL retaining a royalty interest, an equity stake, and exclusive hydrogel manufacturing rights. Additional releases have described expanded partnerships, such as the agreement with STADA Arzneimittel AG involving non-dilutive capital to support product launches and marketing efforts, as well as financing transactions like registered direct offerings and concurrent private placements.
Governance and leadership developments are another recurring news theme. NEXGEL has announced board appointments, conference presentations at investor events, and changes in senior finance roles through its press releases and associated SEC filings. Readers of this NXGL news page can review these updates in one place, including information on special meetings of stockholders, strategic advisors to NexGelRx, and other events that shape the company’s direction.
By monitoring the NXGL news feed, market participants can track how NEXGEL’s hydrogel-focused business, partnerships, financings, and governance decisions evolve over time, using official company communications as a primary source.
NEXGEL, Inc. (NASDAQ: NXGL, NXGLW) announced the appointment of Scott Henry, CFA, as an independent director to its Board of Directors and a member of the Audit Committee, effective immediately. Mr. Henry brings over 20 years of experience in the pharmaceutical and medical device sectors, having previously worked with notable firms like Oppenheimer and Roth Capital Partners. CEO Adam Levy praised his financial expertise and extensive industry network as vital for future growth initiatives. Henry expressed excitement about joining NEXGEL, highlighting the company's solid assets and significant growth potential.
NEXGEL, Inc. has launched a new hydrogel dressing called Turfguard, targeted for athletes to soothe turf burns and protect against infections. Approved by the FDA, Turfguard patches are designed to kill 99% of harmful bacteria, including staph, MRSA, and strep. These patches maintain a moist healing environment and provide cooling relief, making them ideal for treating superficial wounds in sports settings. Manufactured in Langhorne, Pa., Turfguard is now available for purchase on Amazon.com.
NEXGEL, based in Langhorne, PA, has announced a share repurchase program with authorization to buy back up to $500,000 in common shares. This initiative reflects the Company's commitment to enhancing shareholder value, as noted by CEO Adam Levy, who highlighted the attractive investment opportunity represented by the current stock valuation. The repurchases will occur in the open market according to applicable regulations but are not obligatory, allowing flexibility for the Board of Directors to suspend or discontinue the program as needed.
NEXGEL, a leader in high-water-content hydrogel products, announced a virtual fireside chat featuring CEO Adam Levy on December 14, 2022, at 11:00 a.m. ET. The session will cover operational updates, including:
- Positive proof-of-concept results for diclofenac hydrogel patches aimed at treating arthritis and muscle pain.
- Development of a proprietary hydrogel eye patch for treating amblyopia.
- Recent publication of data in SAGE Journals demonstrating significant scar improvement with SilverSeal hydrogel dressing.
Register for the webcast here.
NEXGEL reported a 69.6% year-over-year revenue increase for Q3 2022, totaling $568,000. The gross profit margin improved to 26%, up from a loss the previous year. Cash and equivalents stand at $7.4 million, ensuring operational stability through 2024. The company launched new products and reported positive results from a diclofenac hydrogel study. Despite increased operating expenses, particularly in R&D and SG&A, NEXGEL expects continued revenue and margin growth into 2023.
NEXGEL (NASDAQ: NXGL) will report its third quarter 2022 financial results after market close on November 8, 2022. Following the results, a conference call will be held at 4:30 P.M. ET, which will be accessible via live webcast on NEXGEL's Investor Relations website. A replay will be available until November 15, 2022.
NEXGEL specializes in high-water-content hydrogel products for health and consumer applications and has developed over 200 formulations for gentle skin patches.
NEXGEL (NASDAQ: NXGL, NXGLW) announced positive outcomes from its proof-of-concept study on diclofenac hydrogel patches, aimed at treating pain including arthritis and muscle aches. The study showed that NEXGEL's patches delivered pain relief faster and were longer-acting compared to the leading treatment. These patches adhered to the skin gently for 8-12 hours. CEO Adam Levy expressed optimism about the product's potential and plans for human clinical studies, while seeking strategic partnerships for future development.
NEXGEL (NASDAQ: NXGL, NXGLW) announced the development of a new proprietary hydrogel eye patch to treat amblyopia, commonly known as lazy eye. The patch, expected to be available in the first half of 2023, aims to provide a gentler alternative to traditional eye patches, which can irritate sensitive skin. Amblyopia affects approximately 2-4% of the U.S. population and the global treatment market is projected to exceed $6 billion by 2027. This innovation highlights NEXGEL's commitment to enhancing pediatric care while meeting a growing market demand.
NEXGEL, a provider of high-water-content hydrogel products, announced CEO Adam Levy's participation in two upcoming conferences: the Dawson James Securities 7th Annual Small Cap Growth Conference on October 12, 2022, in Jupiter, Florida, and the LD Micro Main Event XV from October 25-27, 2022, in Los Angeles, California. Levy will speak at the LD Micro conference on October 26 at 8:30 AM PT. Interested investors can schedule 1x1 meetings through their respective representatives.
NEXGEL has announced promising results from a study published in SAGE Journals regarding its SilverSeal hydrogel dressing. The study involved 40 foot and ankle patients and evaluated post-surgical scarring and complications. Results showed that patients using SilverSeal experienced significant improvements in scar quality, reduced pain, and lower itching at the surgical site compared to those with a standard petroleum-based dressing. No postoperative complications were reported in either group, suggesting SilverSeal's potential in enhancing surgical recovery.